The Parkinson's Support Group will hold its monthly meeting at 2 p.m. on Wednesday, Jan. 8, at Sanford Health Windsong, 1010 Anne St. NW. The group meets at 2 p.m. on the second Wednesday of each ...
Psilocybin is under development for the treatment of Parkinson’s disease, bipolar disorder and chronic pain. The drug candidate is a tryptamine alkaloid which acts by targeting 5 hydroxy tryptamine 1A ...
ASN-90 is under clinical development by Asceneuron and currently in Phase I for Parkinson’s Disease. According to GlobalData, Phase I drugs for Parkinson’s Disease have a 72% phase transition success ...